WGS
$76.06-0.04 (-0.06%)
GeneDx Holdings Corp., a genomics company, provides genetic testing services.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also dev...
Recent News
WGS, Zevra Partner to Launch Genetic Testing for Niemann-Pick Type C
GeneDx launches Zevra-backed testing program to expand ExomeDx access for Niemann-Pick Type C, aiming to speed diagnosis and add data to its Infinity dataset.
Can Zevra Therapeutics (ZVRA) Turn NPC Genetic Testing Access Into a Durable Rare-Disease Edge?
In March 2026, GeneDx Holdings Corp. announced a Niemann-Pick disease type C sponsored genetic testing program with Zevra Therapeutics, expanding access to ExomeDx at no cost for eligible U.S. patients and contributing de-identified data to GeneDx Infinity to support faster and more accurate NPC diagnoses. This collaboration strengthens Zevra’s position in rare disease care by directly linking broader genetic testing and earlier NPC identification to potential treatment decisions for its...
Is GeneDx Holdings (WGS) Pricing In Its Sharp 27% Weekly Share Price Move?
If you are wondering whether GeneDx Holdings is pricing in its full potential or still offering room for value, the stock's recent track record gives you a lot to think about. The share price closed at US$94.51, with a 27.4% move over the last 7 days and 12.1% over the last 30 days, set against a year to date return of a 28.6% decline and a 5.4% gain over the past year, while the 3 year return is very large and the 5 year return shows an 84.1% decline. Recent pricing shifts sit against a...
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Ark Invest's CEO kicked off the new trading week with a little shopping.
A Look At GeneDx Holdings (WGS) Valuation After Strong Earnings And Genomics AI Developments
GeneDx Holdings (WGS) is back in focus after reporting quarterly results that included 41% revenue growth in 2025 and earnings ahead of estimates, with the stock recently gaining 7.45%. See our latest analysis for GeneDx Holdings. The recent 7.26% 1 day share price return to US$94.51 builds on a 27.37% 7 day gain and 12.12% 30 day share price return. However, the 90 day share price return of 41.23% and year to date share price return of 28.56% show that momentum is still recovering from...